Advertisement

Prolonged response to aflibercept in ovarian cancer relapse: a case report

Abstract

VEGF-targeted therapies have shown activity in ovarian cancer, and one of them, bevacizumab, has been recently approved in this disease. Aflibercept is an antiangiogenic soluble fusion protein that inhibits VEGF-mediated signaling. In ovarian cancer, phase II trials with aflibercept have shown a significant benefit in the control of malignant ascites but with a lower response rate than expected.

We report the case of a patient with relapsed ovarian cancer treated with aflibercept in fourth line, who experienced a prolonged response during more than two years with good tolerance. The duration of response to aflibercept was longer than that of the three previous lines of therapy (including the initial carboplatin-paclitaxel regimen) and ascites did not reappear. Further clinical research with this drug in ovarian cancer to identify patients who benefit most is warranted.

Tumori 2015; 101(1): e29 - e31

Article Type: CASE REPORT

DOI:10.5301/tj.5000202

Authors

Andrés Redondo, Beatriz Castelo, Alvaro Pinto, Pilar Zamora, Enrique Espinosa

Article History

Disclosures

Informed consent: Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
Financial support: None.
Conflict of interests: The authors declare they have no conflict of interests.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  • Medical Oncology Department, Hospital Universitario La Paz, Madrid - Spain

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.